Beigene (NASDAQ:BGNE)‘s stock had its “buy” rating restated by equities researchers at Cowen in a report released on Monday.

Other analysts have also recently issued reports about the stock. Zacks Investment Research raised shares of Beigene from a “hold” rating to a “buy” rating and set a $115.00 target price on the stock in a report on Tuesday, October 3rd. Maxim Group reissued a “buy” rating and set a $120.00 target price (up from $77.00) on shares of Beigene in a report on Thursday, September 28th. BidaskClub raised shares of Beigene from a “hold” rating to a “buy” rating in a report on Friday, January 5th. Robert W. Baird reissued a “neutral” rating and set a $83.00 target price (up from $58.00) on shares of Beigene in a report on Tuesday, November 14th. Finally, Morgan Stanley reissued an “overweight” rating and set a $95.00 target price (up from $87.00) on shares of Beigene in a report on Friday, October 6th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $96.67.

Shares of Beigene (NASDAQ:BGNE) traded up $2.92 during trading hours on Monday, hitting $100.33. 314,500 shares of the company’s stock were exchanged, compared to its average volume of 184,567. The firm has a market capitalization of $4,560.00 and a PE ratio of -76.59. Beigene has a 52 week low of $30.67 and a 52 week high of $118.95. The company has a quick ratio of 9.27, a current ratio of 9.33 and a debt-to-equity ratio of 0.20.

Beigene (NASDAQ:BGNE) last issued its earnings results on Monday, November 13th. The company reported $2.54 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.23 by $2.31. The business had revenue of $220.21 million for the quarter, compared to analyst estimates of $1.55 million. During the same period last year, the company posted ($1.08) earnings per share. sell-side analysts predict that Beigene will post -2.04 earnings per share for the current fiscal year.

In related news, CMO Amy C. Peterson sold 3,601 shares of the stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $82.96, for a total value of $298,738.96. Following the sale, the chief marketing officer now owns 1,201 shares of the company’s stock, valued at approximately $99,634.96. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO John Oyler sold 150,957 shares of the stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $80.50, for a total transaction of $12,152,038.50. Following the completion of the sale, the chief executive officer now directly owns 491,891 shares in the company, valued at approximately $39,597,225.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 483,482 shares of company stock worth $42,139,474. Corporate insiders own 19.90% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Hillhouse Capital Management Ltd. grew its position in Beigene by 172.6% in the 2nd quarter. Hillhouse Capital Management Ltd. now owns 3,720,726 shares of the company’s stock valued at $167,433,000 after buying an additional 2,355,906 shares in the last quarter. Orbimed Advisors LLC grew its position in Beigene by 2.0% in the 3rd quarter. Orbimed Advisors LLC now owns 1,313,788 shares of the company’s stock valued at $135,925,000 after buying an additional 26,200 shares in the last quarter. Canada Pension Plan Investment Board bought a new position in Beigene in the 3rd quarter valued at about $62,076,000. Artal Group S.A. grew its position in Beigene by 10.1% in the 2nd quarter. Artal Group S.A. now owns 400,000 shares of the company’s stock valued at $18,000,000 after buying an additional 36,714 shares in the last quarter. Finally, Janus Henderson Group PLC bought a new position in Beigene in the 3rd quarter valued at about $33,744,000. Hedge funds and other institutional investors own 55.32% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was first published by Daily Political and is the property of of Daily Political. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2018/01/10/beigene-bgne-stock-rating-reaffirmed-by-cowen.html.

Beigene Company Profile

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Analyst Recommendations for Beigene (NASDAQ:BGNE)

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.